Dr. Reddy’s laboratory. File |Photograph Credit score: The Hindu
Dr. Reddy’s Laboratories has determined to postpone the industrial provide of semaglutide as a result of points associated to the lively pharmaceutical ingredient (API) utilized in semaglutide, an announcement on Thursday (July 9, 2026) that despatched the generic drug maker’s inventory value plummeting.
“A selected batch of semaglutide was discovered to be substandard as a result of a difficulty associated to the lively pharmaceutical ingredient used within the product. Industrial provide of the product can be delayed for a time frame till the difficulty is resolved,” Dr. Reddys mentioned.
We’re investigating the foundation trigger and taking applicable measures to make sure product high quality. The corporate mentioned in its submitting that there is no such thing as a impression on affected person security or the product’s current world regulatory filings.
“We stay dedicated to making sure a dependable world provide of this necessary metabolic remedy,” Dr. Reddys mentioned.
Semaglutide is the lively ingredient in Danish big Novo Nordisk’s blockbuster diabetes and weight reduction medicine Wigoby and Ozempic. Dr. Reddy’s was among the many Indian drug corporations that launched their new drug quickly after the patent on semaglutide expired in March 2026.
Following the launch of Obeda, a generic semaglutide injection for kind 2 diabetes, Dr. Reddy’s launched a semaglutide biosimilar in pill kind underneath the identical model in Could. “With this launch, we develop our GLP‑1 portfolio. As this product is developed and formulated in-house, we’re dedicated to dependable provide and constant high quality to sufferers in India,” mentioned MV Ramana, International Generics CEO.
Shares of Dr Reddy have been down 5.24 per cent at ₹1,278 per share at round 12:30 pm on the BSE. The corporate introduced it could maintain a convention name Thursday night time to debate the event.
